Calcified Tissue International

, Volume 82, Issue 4, pp 249–257 | Cite as

Fracture Risk Associated with Different Types of Oral Corticosteroids and Effect of Termination of Corticosteroids on the Risk of Fractures



We conducted a case–control study on fracture risk associated with the use of orally administered prednisolone/prednisone, budesonide, methylprednisolone, and hydrocortisone to assess if the various preparations were associated with different fracture patterns. Cases were all subjects with any fracture sustained during the year 2000 (n = 124,655). For each case, three controls (n = 373,962) matched on age and gender were randomly drawn from the background population. Adjustments were made for concurrent diseases, use of other drugs, and a number of other factors. Oral prednisolone/prednisone was associated with a dose-dependent increase in fracture risk starting from a dose of around 6.7 mg/day. Oral budesonide was not associated with an increase in overall fracture risk, but the doses in general were low (<3 mg/day). Oral hydrocortisone was not associated with overall risk of fractures. Oral methylprednisolone was only used intermittently and was not associated with an increase in overall fracture risk at the low doses used. After termination of oral prednisolone/prednisone, it took more than 1 year for fracture risk to return to the levels of the background population. Oral prednisolone is associated with a dose-dependent increase in overall fracture risk. Budesonide at low doses did not seem to be associated with fracture risk. Hydrocortisone was not associated with an increase in the risk of fractures. It may take a year from last use of prednisolone/prednisone before fracture risk returns to that of the general population.


Fracture Budesonide Prednisolone Prednisone Hydrocortisone 


  1. 1.
    van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar
  2. 2.
    Vestergaard P, Rejnmark L, Mosekilde L (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257:374–384PubMedGoogle Scholar
  3. 3.
    Suissa S, Baltzan M, Kremer R, Ernst P (2004) Inhaled and Nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169:83–88PubMedCrossRefGoogle Scholar
  4. 4.
    van Staa TP, Leufkens HGM, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588PubMedCrossRefGoogle Scholar
  5. 5.
    van Staa TP, Bishop N, Leufkens HG, Cooper C (2004) Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 15:785–791PubMedCrossRefGoogle Scholar
  6. 6.
    Edsbacker S, Andersson T (2004) Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet 43:803–821PubMedCrossRefGoogle Scholar
  7. 7.
    Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110:1713–1718PubMedCrossRefGoogle Scholar
  8. 8.
    Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapten-White L, Graffner H, Bianchi PG, Vatn M, Stockbrugger RW (2005) Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 3:113–121PubMedCrossRefGoogle Scholar
  9. 9.
    de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRefGoogle Scholar
  10. 10.
    Vestergaard P, Emborg C, Støving RK, Hagen C, Mosekilde L, Brixen K (2002) Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders—a nation-wide register study. Int J Eat Disord 32:301–308PubMedCrossRefGoogle Scholar
  11. 11.
    Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268PubMedGoogle Scholar
  12. 12.
    Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD (1995) The Danish National Patient Register: evaluation of data quality. Ugeskr Læger 157:3741–3745PubMedGoogle Scholar
  13. 13.
    Vestergaard P, Rejnmark L, Mosekilde L (2004) Fracture risk associated with use of anti-epileptic drugs. Epilepsia 45:1330–1337PubMedCrossRefGoogle Scholar
  14. 14.
    Jones S, Johansen A, Brennan J, Butler J, Lyons RA (2004) The effect of socioeconomic deprivation on fracture incidence in the United Kingdom. Osteoporos Int 15:520–524PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ III (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMedGoogle Scholar
  16. 16.
    Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49–52PubMedGoogle Scholar
  17. 17.
    Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL (1996) Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 57:370–376PubMedGoogle Scholar
  18. 18.
    Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1–10PubMedCrossRefGoogle Scholar
  19. 19.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383PubMedCrossRefGoogle Scholar
  20. 20.
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the litterature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRefGoogle Scholar
  21. 21.
    Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L (1999) Fracture risk is increased in epilepsy. Acta Neurol Scand 99:269–275PubMedCrossRefGoogle Scholar
  22. 22.
    Jones G, Nguyen T, Sambrook PN, Eisman JA (1995) Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 10:106–111PubMedCrossRefGoogle Scholar
  23. 23.
    Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316:363–369PubMedGoogle Scholar
  24. 24.
    Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA (2003) Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163:949–957PubMedCrossRefGoogle Scholar
  25. 25.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark. Scand J Public Health 34:371–377PubMedCrossRefGoogle Scholar
  26. 26.
    Munk-Jørgensen P, Mortensen PB (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82–84PubMedGoogle Scholar
  27. 27.
    Edsbacker S, Andersson T (2004) Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet 43:803–821PubMedCrossRefGoogle Scholar
  28. 28.
    Czock D, Keller F, Rasche FM, Haussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61–98PubMedCrossRefGoogle Scholar
  29. 29.
    Dilger K, Schwab M, Fromm MF (2004) Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10:578–583PubMedCrossRefGoogle Scholar
  30. 30.
    Jonsson G, Astrom A, Andersson P (1995) Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 23:137–142PubMedGoogle Scholar
  31. 31.
    van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Fractures and oral corticosteroids: relationship to daily and cumulative dose. Rheumatology 39:1383–1389PubMedCrossRefGoogle Scholar
  32. 32.
    Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G (2003) Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 348:2618–2625PubMedCrossRefGoogle Scholar
  33. 33.
    Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657–666PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Peter Vestergaard
    • 1
    • 2
  • Lars Rejnmark
    • 2
  • Leif Mosekilde
    • 2
  1. 1.The Osteoporosis ClinicAarhus SygehusAarhus CDenmark
  2. 2.Department of Endocrinology and Metabolism CAarhus Sygehus THG, Aarhus University HospitalAarhusDenmark

Personalised recommendations